Serum C-reactive protein: A non-invasive marker of alcoholic hepatitis

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 12, 2006, Pages 1473-1479

  Vanbiervliet, Geoffroy ^a   Le Breton, Frédèrique ^b   Rosenthal Allieri, Maria Alessandra ^a   Gelsi, Eve ^a   Marine Barjoan, Eugenia ^a   Anty, Rodolphe ^a   Piche, Thierry ^a   Benzaken, Sylvia ^a   Saint Paul, Marie Christine ^b   Huet, Pierre Michel ^a   Tran, Albert ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b PASTEUR HOSPITAL   (France)

Author keywords

Acute phase protein; Alcoholic hepatitis; Alcoholic liver disease; C reactive protein; Heavy drinkers

Indexed keywords

ALCOHOL; AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN;

ADULT; ALCOHOL LIVER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; SAMPLE SIZE;

BILIRUBIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HEPATITIS, ALCOHOLIC; HUMANS; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 33751082087     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600842195     Document Type: Article

References (29)

1. Maddrey W. Alcoholic hepatitis: clinicopathologic features and therapy. Semin Liver Dis 1988;3:91-102.
2. Chedid A, Mendenhall C, Gartside P, French S, Chen T, Rabin L. Prognostics factors in alcoholic liver disease. Am J Gastroenterol 1991;86:210-6.
3. Black M, Tavill AS. Corticosteroids in severe alcoholic hepatitis. Ann Intern Med 1989;110:677-80.
4. McClain C, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999;19:205-19.
5. Tilg H, Diehl A. Cytokines in alcoholic and non alcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
6. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349-51.
7. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;15:917-20.
8. Hanck C, Rossol S, Bocker U, Tokus M, Singer MV. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol 1998;33:606-8.
9. Ablij HC, Meinders AE. C-reactive protein: history and revival. Eur J Int Med 2002;13:412-22.
10. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
11. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001;38:189-97.
12. Szalai AJ. The biological functions of C-reactive protein. Vasc Pharmacol 2002;39:105-7.
13. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351-7.
14. Gupta S, Slaughter S, Akriviadis E, Valenzuela R, Deodhar S. Serial measurement of serum C-reactive protein facilitates evaluation in alcoholic hepatitis. Hepatogastroenterology 1995;42:516-21.
15. Michalak S, Rousselet M, Bedossa P, Pilette C, Chappard D, Oberti F, et al. Respective roles of porto-septal fibrosis and centrolobular fibrosis in alcoholic liver disease. J Pathol 2003;201:55-62.
16. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986;6:221-32.
17. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997;181:257-66.
18. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
19. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-90.
20. Anty R, Gual P, Bekri S, Luciani N, Saint Paul MC, Huet PM, et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients with or without type 2 diabetes and NASH. Hepatology 2005;42:624A.
21. Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW. J Exp Med 1993;178:1629-36.
22. Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW. J Immunol 2002;169:7019-25.
23. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. N Engl J Med 2004;350:1387-97.
24. Tall AR. N Engl J Med 2004;350:1450-2.
25. Tommasi S, Carluccio E, Bentivoglio M, Buccolieri M, Mariotti M, Politano M, et al. Am J Cardiol 1999;83:1595-9.
26. Lindahl B, Toss H, Siegbahn, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to longterm mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000;343:1139-47.
27. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-9.
28. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001;103:1194-7.
29. Tilg H, Jalan R, Kaser A, Davies N, Offner F, Hodges S, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-25.